Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of pirfenidone in dermatomyositis-associated interstitial lung disease
CTR20171215Phase 3Active
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirfenidone in dermatomyositis-associated interstitial lung disease (DM-ILD), sponsored by Gyre Pharmaceuticals. Started Jun 2018; status: active.
02
Drugs
pirfenidone
03
Conditions
dermatomyositis-associated interstitial lung disease (DM-ILD)
Beyond the preview
Go deeper on CTR20171215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171215.